Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diranersen (BIIB080) in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia
NCT05399888Phase 2Active, not recruiting
- Sponsor
- Biogen
- Start
- Aug 2022
- Primary completion
- Mar 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of biib080 in Alzheimer's disease (AD) (4 arms), sponsored by Biogen. Primary endpoint: Clinical Dementia Rating-Sum of Boxes at 76 weeks. Started Aug 2022; status: active, not recruiting.
02
Drugs
biib080
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05399888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399888.